<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431961</url>
  </required_header>
  <id_info>
    <org_study_id>DC002544/HIREB3820</org_study_id>
    <nct_id>NCT03431961</nct_id>
  </id_info>
  <brief_title>Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</brief_title>
  <acronym>NACHO</acronym>
  <official_title>Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gail Gauvreau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with allergic asthma developing the required nasal symptoms in response to nasal
      allergen titration during a screening period will be randomized 1:1 to one of 2 cohorts. All
      subjects will have repeated nasal challenges with allergen. One cohort will have nasal saline
      challenge as control. One cohort will have intranasal corticosteroid intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized 1:1 to Cohort A or Cohort B. Each cohort will undergo 3
      nasal challenges, each separated by 3 weeks. Cohort A will undergo 2 nasal allergen
      challenges, and 1 nasal diluent challenge. TNSS, PNIF, spirometry, and samples of blood,
      urine and nasal secretions will be collected until 24h post-challenge to assess
      reproducibility. Cohort B will undergo 3 nasal allergen challenges; one of the challenge will
      be conducted after 14 days treatment with placebo, and one challenge will be conducted after
      14 days treatment with triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg
      administered twice daily for a total daily dose of 440 mcg. TNSS, PNIF, spirometry, and
      samples of blood, urine, nasal secretions will be collected until 24h post-challenge to
      determine reproducibility, and nasal tissue will be collected 24h post-challenge to determine
      effect of steroid treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular inflammation</measure>
    <time_frame>24 hours after nasal allergen challenge</time_frame>
    <description>Nasal eosinophils</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline administered twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>220 mcg administered twice daily for 14 days</description>
    <arm_group_label>Intranasal Corticosteroid</arm_group_label>
    <other_name>Nasacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic rhinitis + mild asthma

        Exclusion Criteria:

          -  other respiratory disease

          -  any medication for treatment of asthma/allergic rhinitis with the exception of
             infrequent beta-2 agonist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail M Gauvreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail M Gauvreau, PhD</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>22791</phone_ext>
    <email>gauvreau@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul M O'Byrne, MB</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>22100</phone_ext>
    <email>obyrnep@mcmaster.ca</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Gail Gauvreau</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

